Dr Eliot Forster to lead MedCity

pharmafile | April 8, 2014 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boris Johnson, medcity 

Dr Eliot Forster has been appointed chairman of MedCity Limited by the London mayor Boris Johnson.

Dr Forster has 20 years of industry experience in biotechnology and pharmaceutical companies. He was most recently the chief executive of Solace Pharmaceuticals, a US-based biotech, before becoming chief executive of European biotech Creabilis.

Prior joining Solace, Dr Forster was Head of EU development and of development operations in the EU & Asia at Pfizer.

During his career at Pfizer Dr Forster was integral to bringing a number of drugs to market, including Celebrex (celecoxib) and Bextra (valcecoxib).

He holds a PhD from Liverpool University and an MBA from Henley Management College.

He has held a number of non-executive director roles in the biotech sector and has been an advisor to the UKTI Life Sciences Strategy Board.

Speaking at the launchof MedCity Dr Forster said: “This is a singular opportunity for this sector to find its rightful place in the world market; to create new companies, new therapies, new investments and to deliver economic and patient benefits.”

Related Content


Valneva COVID-19 vaccine deal pulled by UK government

Boris Johnson and the UK government have terminated its deal with specialist vaccine company Valneva …

G7: UK to donate 100 million surplus vaccine doses

Boris Johnson has announced at the G7 meeting in Cornwall that the UK will donate …


Election Day 2019: Where do the two frontrunners stand on the NHS?

The UK goes to the polls today, for the fourth election of the decade and …

Latest content